Jun 26, 2025 | Industry Trends
FDA Expedited Drug Development Programs The Food and Drug Administration (FDA) follows an established and lengthy approval process that ensures patients have access to therapeutic agents proven to be safe and effective. The process relies upon a structured framework...
Jun 23, 2025 | Business, Data Analytics, Diabetes, Disease Area Trends
Merck’s two blockbuster diabetes products, Janumet® and Januvia®, are DPP-4 inhibitors that generated nearly $3.3 billion in Sales in 2016.3 Januvia® is especially known for its great cardiovascular safety profile, which has helped differentiate itself in its class....
Jun 23, 2025 | Chronic Disease, Diabetes, Disease Area Trends, Heart Disease
When it comes to improving the lives of patients with chronic illnesses like type-2 diabetes and heart disease, the pharmaceutical industry is playing an ever smaller role. New blockbuster drugs are the lifeblood of pharmaceutical companies. Traditionally, they...
Jun 23, 2025 | Business, Industry Trends
M&A mania is here. Unprecedented deal values for mergers and acquisitions dominated in 2014. Worldwide M&A was up 47% since 2013 with 95 deals valued greater than $5 billion, as reported by Reuters. Most deals were transacted in the energy,...
Jun 23, 2025 | Chronic Disease, Diabetes, Disease Area Trends
Novo Nordisk remains a top player in the Diabetes market with blockbuster insulins NovoLog® and Levemir® which brought in a combined almost $3.5 billion in 20166, Victoza® a GLP-1 that brought in $2.1 billion in 20166, and recently launched Basal insulin/GLP-1...
